Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.

P Gallagher; C McGuigan; R Nicholas; J Hobart; H Ford; K Petheram; B Sharrack; N Robertson; G Mazibrada; N Scolding; M Wilson; O Pearson; J Jones; J Overell; ANSWERSMS

doi:10.1177/1352458518798579

Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.

P Gallagher, C McGuigan, R Nicholas, J Hobart, H Ford, K Petheram, B Sharrack, N Robertson, G Mazibrada, N Scolding, M Wilson, O Pearson, J Jones, J Overell, ANSWERSMS

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1177/1352458518798579
Publication status	Published - Oct 2018

Access to Document

10.1177/1352458518798579

Cite this

Gallagher, P., McGuigan, C., Nicholas, R., Hobart, J., Ford, H., Petheram, K., Sharrack, B., Robertson, N., Mazibrada, G., Scolding, N., Wilson, M., Pearson, O., Jones, J., Overell, J., & ANSWERSMS (2018). Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.. https://doi.org/10.1177/1352458518798579

@conference{6f2f1fe769554e598408931578c24faa,

title = "Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.",

author = "P Gallagher and C McGuigan and R Nicholas and J Hobart and H Ford and K Petheram and B Sharrack and N Robertson and G Mazibrada and N Scolding and M Wilson and O Pearson and J Jones and J Overell and ANSWERSMS",

year = "2018",

month = oct,

doi = "10.1177/1352458518798579",

language = "English",

}

TY - CONF

T1 - Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.

AU - Gallagher, P

AU - McGuigan, C

AU - Nicholas, R

AU - Hobart, J

AU - Ford, H

AU - Petheram, K

AU - Sharrack, B

AU - Robertson, N

AU - Mazibrada, G

AU - Scolding, N

AU - Wilson, M

AU - Pearson, O

AU - Jones, J

AU - Overell, J

AU - ANSWERSMS,

PY - 2018/10

Y1 - 2018/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000446861400151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008

U2 - 10.1177/1352458518798579

DO - 10.1177/1352458518798579

M3 - Conference paper (not formally published)

ER -

Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.

Access to Document

Other files and links

Cite this